Brief: Antengene Announces IND Approval In China For Phase Ib/II Study Of ATG-022 In Combination With Keytruda
02/12/2025 09:39
Dec 2 (Reuters) - Antengene Corp Ltd 6996.HK: ANTENGENE ANNOUNCES IND APPROVAL IN CHINA FOR PHASE IB/II STUDY OF ATG-022 (CLDN18.2 ADC) IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) ± CHEMOTHERAPY Source text: ID:nPn3vWhNGa Further company coverage: 6996.HK ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106